Exact Sciences Corp. (NASDAQ:EXAS)’s share price dropped 1.5% during trading on Thursday . The stock traded as low as $12.51 and last traded at $12.90, with a volume of 1,973,109 shares trading hands. The stock had previously closed at $13.10.

EXAS has been the topic of several recent analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $9.00 target price on shares of Exact Sciences Corp. in a report on Monday, May 2nd. Zacks Investment Research raised Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Tuesday, April 26th. Jefferies Group reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, May 4th. BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Finally, William Blair reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $11.52.

The company’s 50 day moving average price is $10.09 and its 200 day moving average price is $7.44. The stock’s market capitalization is $1.27 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same period in the prior year, the company earned ($0.40) EPS. The business had revenue of $14.80 million for the quarter, compared to the consensus estimate of $15.17 million. Exact Sciences Corp.’s quarterly revenue was up 244.2% on a year-over-year basis. Analysts forecast that Exact Sciences Corp. will post ($2.00) EPS for the current year.

Other large investors have made changes to their positions in the company. Eagle Asset Management acquired a new stake in shares of Exact Sciences Corp. during the third quarter worth $39,880,000. OppenheimerFunds Inc. increased its stake in shares of Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock worth $25,636,000 after buying an additional 2,277,430 shares in the last quarter. US Bancorp DE increased its stake in shares of Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock worth $2,119,000 after buying an additional 5,109 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock worth $1,640,000 after buying an additional 2,809 shares in the last quarter.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.